NCT03800979View on ClinicalTrials.gov

Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 12, 2019

Primary Completion Date

January 30, 2021

Study Completion Date

January 30, 2021

Conditions
Alopecia Areata
Interventions
DRUG

Tofacitinib

Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.

Trial Locations (1)

Unknown

Institute of Dermatology, Bangkok

All Listed Sponsors
lead

Institute of Dermatology, Thailand

OTHER_GOV

NCT03800979 - Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata | Biotech Hunter | Biotech Hunter